US genomics startup Omicia picks up $6.8M in Series A round
Omicia has secured $6.8 million in a Series A funding led by Artis Ventures. Bay City Capital, Buchanan Investments, Casdin Capital, and Acadia Woods Partners also participated in the round. Bay City will be adding partners to the startup's board, according to VentureBeat.
As more and more genetic data are collected, Omicia has developed a system that analyzes human genome sequences. The company wants to help researchers and medical professionals use stored genome data. The University of Utah uses the firm's Opal IT product for the genome sequencing of 3,000 individuals for 15 different illnesses, the report detailed.
Artis Ventures president and founder Stuart Peterson said in a press release: "Clinical genomics is taking off. Top tier medical institutions are using the big data of next-generation sequencing to further distinguish themselves, and Opal is proving to be the optimal platform to achieve this."
The firm will use the new capital for the expansion of its marketing efforts and optimization of its big data portfolio, Omicia's press release said. The company is presently based in Oakland, California and is hiring data scientists, bioinformaticians, and software engineers, VentureBeat reported.